MECHELEN, Belgium, Nov. 24, 2016 -- Galapagos NV (Euronext & NASDAQ: GLPG) announces that Stoxx has selected Galapagos NV for inclusion in the Stoxx Europe 600 Index, effective 19 December 2016.
"After the inclusion of Galapagos in the BEL20 Index last March and, as first biotechnology company ever, in the AEX Index last June, we are pleased to be subsequently selected for inclusion in the Stoxx Europe 600 Index as well. The year 2016 has truly reflected the evolution of Galapagos from a pioneering target discovery company to an integrated biopharmaceutical powerhouse," says Onno van de Stolpe, CEO and Founder.
Stoxx Ltd. is a global index provider, currently calculating a global, comprehensive index family of over 7,500 strictly rules-based and transparent indices. Best known for the leading European equity indices EURO Stoxx 50, Stoxx Europe 50 and Stoxx Europe 600, Stoxx Ltd. maintains and calculates the Stoxx Global index family which consists of total market, broad and blue-chip indices for the regions Americas, Europe, Asia/Pacific and sub-regions Latin America and BRIC (Brazil, Russia, India and China) as well as global markets.[1]
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 480 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
| VP IR & Corporate Communications +1 781 460 1784 | Director Communications +31 6 53 591 999 [email protected] |
| Paul van der Horst Director IR & Business Development +31 6 53 725 199 | |
| [email protected] |
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
[1] Source: www.stoxx.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/07b312c6-b578-4d03-b8e2-2aaaa78ea2ee


Britain Courts Anthropic Amid US Defense Department Dispute
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
First Western Ship Transits Strait of Hormuz Since Iran War Began
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 



